vTv Therapeutics (VTVT) Income from Continuing Operations (2016 - 2025)
Historic Income from Continuing Operations for vTv Therapeutics (VTVT) over the last 12 years, with Q3 2025 value amounting to -$10.3 million.
- vTv Therapeutics' Income from Continuing Operations fell 7714.04% to -$10.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$28.4 million, marking a year-over-year decrease of 2496.81%. This contributed to the annual value of -$22.7 million for FY2024, which is 1255.87% up from last year.
- According to the latest figures from Q3 2025, vTv Therapeutics' Income from Continuing Operations is -$10.3 million, which was down 7714.04% from -$7.4 million recorded in Q2 2025.
- In the past 5 years, vTv Therapeutics' Income from Continuing Operations ranged from a high of -$841000.0 in Q2 2021 and a low of -$10.3 million during Q3 2025
- Moreover, its 5-year median value for Income from Continuing Operations was -$6.0 million (2024), whereas its average is -$6.1 million.
- Examining YoY changes over the last 5 years, vTv Therapeutics' Income from Continuing Operations showed a top increase of 8314.97% in 2021 and a maximum decrease of 69010.58% in 2021.
- vTv Therapeutics' Income from Continuing Operations (Quarter) stood at -$9.5 million in 2021, then skyrocketed by 35.78% to -$6.1 million in 2022, then increased by 27.08% to -$4.4 million in 2023, then increased by 0.09% to -$4.4 million in 2024, then crashed by 133.15% to -$10.3 million in 2025.
- Its last three reported values are -$10.3 million in Q3 2025, -$7.4 million for Q2 2025, and -$6.2 million during Q1 2025.